I.V. opioids have been used by continuous infusion to achieve analgesia during cardiac anaesthesia. Recent reports indicate that high intraoperative administration of opioids not only increase postoperative pain and postoperative morphine consumption, 1 but also induce significant postoperative allodynia and hyperalgesia. 2 3 It has been suggested that reduction in the intraoperative opioid dose would decrease postoperative hyperalgesia. 4 5 High intraoperative opioid consumption has also been associated with postoperative cognitive dysfunction, which has been raised as a significant marker of patient outcome after cardiac surgery. 6 Targetcontrolled infusion (TCI) of opioids has been shown not only to improve intraoperative haemodynamic stability but also to decrease intraoperative opioid requirements. 5 Sufentanil is commonly used during cardiac anaesthesia and several pharmacokinetic models have been developed to facilitate its administration. The effects of pathophysiological changes associated with CPB may considerably affect the pharmacokinetics of sufentanil, but these have not been thoroughly addressed. Early investigations regarding the impact of cardiopulmonary bypass (CPB) on the pharmacokinetics of sufentanil reported significant changes in pharmacokinetics but suggested that these may be clinically insignificant. 7 8 However, significant inaccuracies between measured and model-predicted sufentanil drug concentrations have been reported to occur during CPB when sufentanil was administered with TCI. 9 Drug effect is the amount of drug not bound in plasma proteins or blood cells. To our knowledge, there is no previous information on the effect of CPB on the free amount of sufentanil. We therefore studied the pharmacokinetics of sufentanil when administered as TCI during coronary artery bypass surgery with special emphasis to the unbound sufentanil concentration. Our primary study goal was to investigate whether the Gepts model, 10 which is implemented in commercially available TCI pumps, produces constant total, unbound sufentanil concentrations or both in patients during coronary artery bypass surgery with CPB. Secondly, we derived a pharmacokinetic model for sufentanil from this patient collective and compared its predictive ability with that of the Gepts model.
Methods
The study was performed between March 2007 and April 2010. As patient enrolment started before 2009, the study was not registered in a public clinical trials registry, but was conducted in accordance with the guidelines for Good Clinic- 
Patients
The data reported in the present manuscript were collected within a study on the influence of intraoperative opioid dosing on postoperative pain and morphine consumption after cardiac surgery. 11 After receiving written informed consent, 38 male adult patients undergoing elective first time coronary artery bypass graft (CABG) surgery were enrolled for anaesthesia with sufentanil. Inclusion criteria were an age between 40 and 75 years, ASA physical status of III, and a left ventricular ejection fraction of at least 40%. Patients with diabetes mellitus, or a medical history of renal, neurological, or chronic inflammatory disease were excluded from the study. Further exclusion criteria were anamnestic drug abuse and the use of non-steroidal antiinflammatory drugs or opioids for pain therapy before the start of the study. Body mass index and body surface area were determined from bodyweight and height. 12 
Clinical protocol
After a premedication with 7. 10 The patients were randomized into two treatment groups with target concentrations of 0.4 or 0.8 ng ml 21 . These target concentrations were kept constant, beginning at least 20 min before skin incision until last skin suture. During induction of anaesthesia, the target concentrations were 0.4-1.5 ng ml 21 . The CPB circuit was primed with 500 ml of Ringer's solution, 500 ml of 6% Voluven w , and 500 ml of 10% Mannitol w supplemented with 5000 IE of Heparin and 2 g of tranexamic acid. The bypass was conducted using normothermia, nonpulsatile blood flow, and a-stat pH management. After the end of the surgery, the patients were transferred to the ICU and the propofol infusion was continued for further 2 -3 h with an infusion rate of 2.5 mg kg 21 h 21 .
Sampling
Blood samples were drawn from an artery line into ethylenediaminetetraacetic acid-containing tubes (S-Monovette w Kalium EDTA, Sarstedt, Nü rnbrecht, Germany) immediately before the induction of anaesthesia and at six predefined time points during the surgical procedure: just before skin incision, 5 min before CPB, 15 and 45 min after the beginning of CPB, 15 min after the end of CPB, and at the skin closure.
To determine the arterial sufentanil concentrations, 8 ml blood were drawn per sample, after 1 ml blood had been drawn and discarded. After each sample collection, the intra-arterial catheter was flushed with 2 ml of heparinized NaCl solution. Plasma was separated immediately and stored on ice until extraction and assay.
Drug analysis
Plasma concentrations of total and unbound sufentanil were quantified by the use of a Waters Alliance HPLC system (Waters, Eschborn, Germany) coupled to a Waters Quattro Micro triple quadrupole mass spectrometer with Z-spray electrospray source. 15 The chromatography system was upgraded and modified by Fischer Analytics (Bingen, Germany) to allow the system running UPLC-like pressures of more than 400 bar. For the estimation of the free fraction levels of sufentanil plasma proteins were separated from the plasma samples using Centrifree filter units (Millipore, Schwalbach, Germany). For the assay, ultrafiltrated samples (for unbound sufentanil concentrations) and plasma samples (for total sufentanil concentrations) were supplied to ISOLUTE solid phase extraction cartridges. The analytes were eluted and the eluate was evaporated to dryness at 378C under a stream of nitrogen and resolved again. Chromatographic separation was carried out with a Kinetex C18 column (50×2.1 mm) from Phenomenex (Aschaffenburg, Germany). The data were acquired using positive electrospray mode with multiple-reactions monitoring. The product ion was 238.27 m/z for sufentanil (387.14 to .238.27 m/z). The quantitation limit for sufentanil was 5 pg ml 21 and the interday coefficient of variation was 9.7, 4.3, and 6.5% at 5, 250, and 2500 pg ml 21 , respectively (n¼15 for each concentration).
Data analysis
To characterize the time course of the measured total and unbound sufentanil concentrations and to normalize the concentrations with respect to the two target groups, we calculated the ratios C Total /C Target and C unbound /C Target for each blood sample. We further determined the free fraction of sufentanil C unbound /C Total . These ratios were tested for timerelated changes (see Statistics). The performance of the TCI model was assessed by the prediction error PE¼(C Total 2 C Target )/C Target . To characterize the TCI performance before cardiopulmonary bypass (Pre-CPB), during CPB, and after cardiopulmonary bypass (Post-CPB), we calculated the median prediction error (MDPE) and the median absolute prediction error (MDAPE) in these periods.
Pharmacokinetic modelling
A pharmacokinetic model was determined using NONMEM (Version 7.2, ICON Development solutions, Ellicot City, MD, USA). The first-order conditional estimation method with interaction was used throughout the analysis. Interindividual variability of the pharmacokinetic parameters was estimated using log-normal distributions with mean zero and variance v 2 , and intra-individual variability was estimated using a combined proportional and additive error model with means of zero and variances s 1 2 and s 2 2 . One-, two-, and three-compartment models with first-order elimination were fitted to the data with volumes of distribution, and elimination and intercompartmental clearances as model parameters. The infusion rates obtained from the TCI device were used as input of the pharmacokinetic model. It was assumed that clearances and volumes of distribution may be different in the three periods (Pre-CPB, CPB, Post-CPB). Therefore, we tested systematically different complex models, starting with the simplest model where all clearances and volumes were constant throughout all periods, and adding step by step additional parameters allowing different values for different periods, ending up with the most complex model, having three different values for each clearance and volume. Subsequently, backward deletion analysis was performed. The influence of age and body weight on pharmacokinetic parameters was assessed by testing linear relationships, and also an allometric power model for the effect of body weight. Models were compared by the likelihood test using the difference in the NONMEM objective function value (DOFV) at a significance level of P,0.05. Goodness of fit was assessed by visual inspection of the following plots: measured concentrations vs population (PRED) and individual predictions (IPRED), conditional weighted residuals (CWRES) vs PRED and CWRES vs time. MDPE and MDAPE were calculated for both PRED and IPRED. To evaluate the predictability of the model, visual predictive checks were performed by simulating 1000 datasets. Using the final model and the original data set, bootstrap resampling analysis with 1000 replicates (by subject with replacement) was conducted for validation of the model and to obtain non-parametric confidence intervals of the final population model parameters.
Statistics
Data were tested for normal distribution using the ShapiroWilk's test. Time-related changes of the ratios C Total /C Target and C unbound /C Target , of the free fraction of sufentanil, and of the laboratory and haemodynamic data were tested by ordinary repeated measurement ANOVA if they were normally distributed, and otherwise by Friedman's ANOVA. At each of the six sampling time points, it was further tested whether the ratio C Total /C Target was significantly different from 1 (one sample t-test or Wilcoxon test, with Bonferroni correction).
In a previous study, the MDPE for sufentanil TCI was 21.7 (20)%. 8 If one considers a deviation from the target of more than 10% (i.e. C Total /C Target less than 0.9 or greater than 1.1) as significant, one needs at least 34 patients to detect such a bias with a power of 80% and P,0.05, assuming a standard deviation of 20%. Differences between the two sufentanil target groups regarding patient characteristics, concentration/target ratios, and free fraction of sufentanil were identified using the t-test or the Mann-Whitney test, respectively. Statistical analysis was performed with Statistica 6.0 (StatSoft Inc., Tulsa, OK, USA). The data are presented as mean (SD) unless otherwise stated.
Results
From the 38 patients included in the study, 18 patients received a TCI of sufentanil with 0.4 ng ml 21 , and 20 patients Table 1 . The two target groups were different only with respect to the administered sufentanil dose. Table 2 summarizes laboratory, haemodynamic data, and temperature. All these parameters remained within the expected clinical ranges throughout the surgical procedure, although haematocrit was significantly lower during and after CPB when compared with Pre-CPB (P,0.01). During induction of anaesthesia, the maximum sufentanil target concentration was 1.1 (0.3) ng ml 21 . After intubation, the sufentanil target concentration was set to the predefined level of 0.4 or 0.8 ng ml 21 . Based on the prediction by the TCI model, this final sufentanil target was reached 15 (12) min after start of anaesthesia, and the first blood sample was taken 64 (22) min after start of anaesthesia. Figure 1 shows the results for the sufentanil concentration data. We observed a significant change of the ratio C Total / C Target over time (P,0.001). The measured total sufentanil concentrations were significantly higher than targeted during the Pre-CPB period (P,0.001), and decreased subsequently. The unbound sufentanil concentration also showed significant changes during the course of anaesthesia with higher values during CPB (P,0.001). Thus, the changes seen were opposite to the changes in total sufentanil concentrations. Accordingly, the free fraction of sufentanil showed a significant trend (P,0.001) with clearly increased values during CPB. The ratios C Total /C Target and C unbound / C Target as well as the free fraction were not statistically different between the two treatment groups. The prediction errors in Table 3 also demonstrate the distinct bias of the TCI model in the Pre-CPB phase.
The pharmacokinetic modelling of the total sufentanil concentration was best achieved with a two-compartment model with significant changes of the parameters between the three periods: the elimination clearance CL 1 and the intercompartmental clearance CL 2 increased from Pre-CPB to CPB and remained constant thereafter; the central volume of distribution V 1 remained constant in Pre-CPB and CPB, and increased in post-CPB; the peripheral volume of distribution V 2 remained constant within all periods. This two-compartment model with seven parameters was ) to normalize the data. *At the beginning of surgery and 5 min before the start of CPB, the ratio C Total /C Target was significantly different from 1 (P,0.001). significantly better than the simple two-compartment model with constant values of all four pharmacokinetic parameters (DOFV¼149.1, P,0.001), and it was also significantly better than a one-compartment model with three different values of CL 1 and V 1 for the three periods (DOFV¼20.8, P,0.001). However, it was not possible to estimate the interindividual variance of CL 2 which was therefore fixed to zero. A threecompartment model could not be estimated reliably. There was no significant influence of age and body weight on the pharmacokinetics of sufentanil. Table 4 summarizes the population pharmacokinetic parameter estimates of the final model, which showed a good quality of fit with conditional weighted residuals being randomly and homogenously distributed (Fig. 2) . Median and 95% confidence intervals of the bootstrap revealed an acceptable agreement between the population and the bootstrap estimates. During Pre-CPB, the prediction errors of the final model were lower than the prediction errors of the TCI model (Table 3) . Visual predictive check did not indicate any apparent deviations between the model and original data (Fig. 3) . The measured and predicted concentrations for one single case are depicted in Figure 4 .
Discussion
Our results indicate that TCI using the Gepts model was not accurate during the pre-bypass phase but resulted in significantly higher sufentanil plasma concentrations than targeted. The total sufentanil concentrations decreased subsequently, whereas the unbound sufentanil concentrations increased. These changes summed up in a significant increase in sufentanil-free fraction during the CPB. If one considers the achievement of constant concentration levels as a main objective of TCI, one would therefore conclude that the Gepts model is not suitable for cardiac anaesthesia with CPB, although it is currently the only model which is available in commercial TCI pumps. As this model was derived from a patient group undergoing non-cardiac surgery, it may not be so surprising, that the accuracy of this model was not very good when used for a population of patients having cardiac surgery with CPB.
There are only few reports in the literature about the predictive performance of sufentanil TCI during cardiac surgery with CPB. Hudson et al.
8 administered sufentanil for cardiac surgery patients using not the Gepts model but a pharmacokinetic model that had been developed from Pre-CPB data in cardiac patients. 7 Unfortunately, they did not report the performance error of this model when used for TCI, but developed a new model whose pharmacokinetic parameters were different from their initial TCI model. Bailey et al.
16
used for cardiac anaesthesia an older model from Hudson, which had been developed from abdominal aortic surgery, 17 and reported measured concentrations which were about 100% higher than targeted. The only study with sufentanil TCI in cardiac anaesthesia using the Gepts model was conducted by Barvais et al. 9 They reported only a slight overprediction before CPB (MDPE¼26.8%), but a clear overprediction during and after CPB when the measured concentrations were 42% lower than targeted. Such a decrease in the total sufentanil concentration after start of CPB was also seen in our study (Fig. 1) , but the absolute levels were shifted, showing much higher concentrations than targeted before CPB but not during and after CPB. Reasons for these different findings may include differences in the study populations and in the amount of sufentanil given during anaesthesia. High sufentanil target used during the induction of anaesthesia could have led to the distinct overshoot of sufentanil concentrations in the first two blood samples, given that the predicted sufentanil concentration had not reached the target at that time of sampling. However, the predicted sufentanil concentration (based on the Gepts TCI model) decreased relatively fast (Fig. 4) after the end of induction. Therefore, when the first blood sample was taken approximately 65 min after the start, the predicted concentration had reached the final sufentanil target of 0.4 or 0.8 ng ml 21 . Furthermore, one cannot rule out also pharmacokinetic interactions, as Hudson et al. used isoflurane, and Barvais et al. used midazolam as anaesthetic whereas we used propofol. As propofol decreases cardiac output 18 and hepatic blood flow, 19 coadministration of propofol may reduce the clearance of sufentanil as sufentanil has a high extraction ratio of at least 0.8, 20 which means that its elimination clearance depends mainly on liver blood flow. Consequently, coadministration of propofol may have caused increased sufentanil concentrations in our study. The observed changes in total concentrations were reflected by corresponding changes in the pharmacokinetic parameters. Both elimination and intercompartmental clearance increased significantly after the onset of CPB, whereas the central volume of distribution did not change until the end of CPB, and the peripheral volume of distribution did not show any alteration. As our six blood samples were taken during the maintenance phase of TCI, elimination and intercompartmental clearance are the pharmacokinetic parameters with the highest impact on measured concentration. The finding that CL 1 remained at this high value after cessation of CPB may be explained by the better cardiac performance of the heart and in part also by the increased heart rate caused by vasoactive chronotropic drugs administered after CPB. Whereas the effect of CPB on clearance was quite obvious, we did not observe an effect of CPB initiation on volume of distribution, although the priming of the bypass circuit with crystalloids causes haemodilution, 22 which was also indicated by the decrease in haematocrit in the present study (Table 2 ). However, changes in the central volume of distribution have been shown to balance out quickly by redistribution of sufentanil from peripheral compartments. 23 One would therefore expect that the total sufentanil should show an initial decrease shortly after start of CPB, followed by a return to prebypass levels, as it has been shown previously for propofol and midazolam. 24 25 However, we did not have repeated sampling during the initiation of CPB, thus we cannot rule out the possible effect of haemodilution immediately after start of CPB. Fifteen minutes later, when our first CPB sample was taken, the redistribution was most probably terminated, and the change of elimination and intercompartmental clearance was then the dominant effect. The increase in V 1 after cessation of CPB remains unclear. Sufentanil pharmacokinetics were best described by a two-compartment model with satisfactory precision as judged with goodness-of-fit plots and visual predictive check. Three-compartment models have been used in earlier studies to describe the pharmacokinetics of sufentanil 8 10 and we tested a three-compartment model also, but this model was discarded as no stable estimates were produced. This was mainly because of the sparse sampling which is clearly a limitation of this study. The larger standard errors of V 1 and V 2 are also a consequence of the sampling design, which allowed primarily the estimation of clearances. However, we were mainly interested in longer lasting effects and the primary aim was to investigate the predictive performance of TCI during anaesthesia maintenance, therefore we decided to draw only few representative samples. Based on the present findings it would, however, be worth to conduct a pharmacokinetic study with higher sampling resolution. Having more data, it may also be possible to directly model the observed changes in clearance and volume of distribution as a function of cardiac output and protein binding. Furthermore, inclusion of cardiac output being measured during anaesthesia as a covariate may particularly result in an improved TCI model, although there may exist an inherent difficulty to describe in one pharmacokinetic model all three phases (before, during, and after) of cardiac surgery with CPB.
It is a common observation during anaesthesia that large interindividual variability exists between patients regarding the various aspects of nociception. Recent studies indicate that the amount of opioid given intraoperatively affects the postoperative opioid consumption and occurrence of hyperalgesia. 1 2 5 6 26 As the pharmacological effect is related to the unbound drug concentration, our finding that unbound sufentanil plasma concentrations increased during cardiac surgery with TCI is of some importance. During CPB, the increase in the free fraction compensated the decrease in total sufentanil concentration resulting in slightly increasing unbound concentration. This may help prevent inadequate analgesia caused by a decrease in the subtherapeutic levels, but could theoretically also result in postoperative hyperalgesia as a consequence of too high sufentanil exposure.
In conclusion, our results demonstrated that dosing based on the Gepts model led to an overshoot of total sufentanil concentrations at the beginning of cardiac anaesthesia. Also, the observed higher unbound sufentanil concentrations during CPB may have an impact in postoperative pain therapy. Pharmacokinetic analysis showed that CPB influenced sufentanil intercompartmental and elimination clearances significantly. However, because of a sparse sampling in the present trial, further studies are warranted to confirm the present results.
